Aml bfm study group

International BFM Study Group – I-BFM-SG

★ ★ ★ ★ ★

I-BFM is a globally renowned group doing research on every aspect related to paediatric leukaemias and lymphomas.Since more than 40 years, the I-BFM network works to advance the cure rate and the quality of life of children and adolescents with paediatric haematological malignancies.. Paediatric cancer is rare, but it is one of the main causes of death by disease in children and adolescents.

International BFM Study Group – I-BFM-SG

Acute myelogenous leukaemia in children under 2 years ...

★ ★ ★ ★ ☆

Clinical, morphological, immunological, cytogenetical and prognostic features of 84 children under 2 years of age with AML in studies AML-BFM-78, -83 and -87 were retrospectively analysed. There was a high incidence of acute monoblastic leukaemia (FAB M5) (41 patients--49%) and acute ...

Acute myelogenous leukaemia in children under 2 years ...

Ongoing Trials – International BFM Study Group

★ ★ ☆ ☆ ☆

Ongoing studies ALL INTERFANT-06: Randomized clinical trial for ALL under 1y* ALLIC-BFM 2002 (2002-2009 ): Randomized clinical protocol for ALL in countries with limited resources ALL-SCT BFM 2003: HSCT* in VHR ALL AIEOP-BFM ALL 2009: Randomized clinical trial for ALL (age 1-18y) Germany ALL IC-BFM 2009 *web-based trials Ongoing studies AML ICC APL Study 01…

Ongoing Trials – International BFM Study Group

Study AML-BFM 2004: Improved Survival In Childhood Acute ...

★ ★ ★ ★ ☆

11/19/2010 · Abstract 181 Acute Myeloid Leukemia - Therapy, excluding Transplantation: Pediatric and Adult AML Therapy Study AML-BFM 2004 was designed to improve outcome of children and adolescents with AML without increasing toxicity. Patients were stratified into a standard- (SR)* or high-risk (HR)** group according to morphology, cyto-/molecular genetics including FLT3-ITD, and therapy response …

Study AML-BFM 2004: Improved Survival In Childhood Acute ...

Favorable outcome in infants with AML after intensive ...

★ ★ ★ ★ ★

10/4/2011 · Results of studies AML-BFM-98 and -2004 show that the outcome in infants could be improved compared with the earlier studies, 20 leading to a 5-year survival rate of 75% in study AML-BFM …

Favorable outcome in infants with AML after intensive ...

Myelodysplasia and acute myelogenous leukemia in Down's ...

★ ★ ★ ☆ ☆

Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Creutzig U(1), Ritter J, Vormoor J, Ludwig WD, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J.

Myelodysplasia and acute myelogenous leukemia in Down's ...

Gemtuzumab in Children with Relapsed and ... - Blood Journal

★ ★ ★ ★ ★

12/2/2016 · BACKGROUND: Long-term survival in pediatric acute myeloid leukemia (AML) improved remarkably during the last decades. However, children with refractory disease or relapsed AML still suffer from exceedingly poor outcome, especially those who relapse within one year of diagnosis with very limited treatment options. Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody linked to …

Gemtuzumab in Children with Relapsed and ... - Blood Journal

(PDF) Favourable outcome of patients with childhood acute ...

★ ★ ☆ ☆ ☆

AML-BFM study group, a learning effect concerning the. management of early complications, such as haemorrhage or. infections was seen over time, from study to study (Creutzig. et al, 2004).

(PDF) Favourable outcome of patients with childhood acute ...

Identification of two risk groups in childhood acute ...

★ ★ ★ ☆ ☆

AML IN CHILDHOOD RISK GROUPS 1933 Treatment In study AML-BFM-78, initial therapy, adapted from the West Berlin ALL protocol, consisted of a seven-drug induction/consolida- …

Identification of two risk groups in childhood acute ...

Successes and challenges in the treatment of pediatric ...

★ ★ ☆ ☆ ☆

2/22/2018 · Since 11/2001, a randomized phase III study (AML-2001/01) was opened by the International BFM (I-BFM) Study Group for pediatric patients with relapsed AML with FLAG (fludarabine, cytarabine ...

Successes and challenges in the treatment of pediatric ...

Favorable outcome in infants with AML after intensive ...

★ ★ ★ ★ ☆

Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Download. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. B. Kremens.

Favorable outcome in infants with AML after intensive ...

AML-BFM 2012: clinical trial for the treatment of acute ...

★ ★ ★ ★ ☆

AML-BFM 2012 Study hypothesis. 1. Improvement in the event-free and overall survival of children and adolescents with acute myeloid leukemia (AML) through the introduction of …

AML-BFM 2012: clinical trial for the treatment of acute ...

Pediatric Acute Myelocytic Leukemia: Practice Essentials ...

★ ★ ★ ★ ★

9/12/2017 · Acute myeloid (myelogenous, myelocytic, myeloblastic) leukemia (AML) consists of a group of malignant disorders characterized by the replacement of normal bone marrow with abnormal, primitive hematopoietic cells. Although the cure rate has improved, treatments are associated with notable morbidity and mortality.

Pediatric Acute Myelocytic Leukemia: Practice Essentials ...

AML-BFM STUDY GROUP | Researcher Profile | SYMPTOMA.com

★ ★ ★ ★ ★

Title and Abstract from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. Data mined from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

AML-BFM STUDY GROUP | Researcher Profile | SYMPTOMA.com

Second national study AML-BFM 98 improved remission rate ...

★ ★ ★ ★ ☆

EFS/OS in standard risk patients was 52.9/76.6%, in high risk 36.1/44.4%. The previous AML-BFM 93 study achieved 5-year EFS/OS 42.6/45.9% in the Czech Republic. Altogether, 473 patients were enrolled in the international AML-BFM 98 study and 88% of them achieved complete remission with 5 …

Second national study AML-BFM 98 improved remission rate ...

Improved outcome of pediatric patients with acute ...

★ ★ ★ ★ ☆

nosed with AMKL by the BFM Study Group in the studies AML-BFM 98 (n=37) and AML-BFM 04 (n=60), including patients younger than 18 years with de novoAMKL. Patients with DS, myelosarcoma, secondary AML, or pretreatment of more than 2 weeks were excluded. Treatment plan Children with non-DS-AMKL were treated according to re-

Improved outcome of pediatric patients with acute ...

Differences in infection prophylaxis measures between ...

★ ★ ☆ ☆ ☆

However, recommendations are often non‐specific and supported by low‐quality evidence, resulting in divergent infection preventive regimens. Using a web‐based survey, we investigated the infection prophylaxis guidelines of 22 paediatric AML study groups affiliated to the international Berlin–Frankfürt–Münster study group.

Differences in infection prophylaxis measures between ...

The Childhood AML Studies BFM-78 and -83: Treatment ...

★ ★ ★ ★ ☆

The Childhood AML Studies BFM-78 and -83: Treatment Results and Risk Factor Analysis * U. Creutzig, J. Ritter, H. Riehm, M. Budde, and G. Schellong1 ... 1 For the BFM-AML Study Group: University children's Hospital, D-4400 Miinster, Federal Republic of Germany.

The Childhood AML Studies BFM-78 and -83: Treatment ...

Treatment results in children with myeloid leukemia of ...

★ ★ ★ ★ ☆

Treatment results in children with myeloid leukemia of Down syndrome in Saudi Arabia: A multicenter SAPHOS leukemia group study ... syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia, 19 ... of childhood de novo acute myeloid leukemia in Saudi Arabia: a multicenter SAPHOS leukemia group study. Leuk. Res., 49

Treatment results in children with myeloid leukemia of ...

Immunophenotypic Differences Between Diagnosis and Relapse ...

★ ★ ★ ☆ ☆

criteria of the French-American-British group by the refer-ence laboratory of the AML-BFM studies in Mu¨nster and reviewed by an expert group of extern hematologists. Cytogenetics and Molecular Genetics Cytogenetic analyses were performed in the reference laboratory of the AML-BFM …

Immunophenotypic Differences Between Diagnosis and Relapse ...

Clinical implications of PRAME gene expression in ...

★ ★ ☆ ☆ ☆

Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. ... A. FeldgesIdarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM study group. ... result of study AML-BFM-87.

Clinical implications of PRAME gene expression in ...

MRD-AML-BFM STUDY GROUP | Researcher Profile | Symptoma.com

★ ★ ★ ★ ★

Title and Abstract from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. Data mined from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MRD-AML-BFM STUDY GROUP | Researcher Profile | Symptoma.com

UpToDate

★ ★ ★ ☆ ☆

Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013; 31:599. Lipshultz SE, Franco VI, Miller TL, et al. Cardiovascular disease in adult survivors of childhood cancer.

UpToDate

Infectious complications in pediatric acute myeloid ...

★ ★ ★ ★ ★

A report of 40 children of the AML-BFM Study received anthracyclines in a reduced dosage and consolidation Group. Leukemia 1996; 10: 1677–1686. ... Sepsis, and Infectious Death in Pediatric Acute Myeloid Leukemia (AML): Results From the Canadian Infections in …

Infectious complications in pediatric acute myeloid ...

leukemiawithadistinct HOX geneexpressionpattern

★ ★ ★ ☆ ☆

was restricted to patients with de novo AML enrolled in Dutch Childhood Oncology Group and AML-BFM Study Group studies, excluding PML/ RARA cases (n 238). The median follow-up time of survivors of 4.2 years (range, 0.3-22.7 years), and overall probability of event-free survival (pEFS) and probability of overall survival (pOS) for the pediatric

leukemiawithadistinct HOX geneexpressionpattern

Favorable outcome in infants with AML after intensive ...

★ ★ ★ ★ ☆

Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia. 2012; 26(4) ... A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n = 59) and -2004 (n = 66). Treatment regimens of both studies were comparable, consisting of intensive ...

Favorable outcome in infants with AML after intensive ...

Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24 ...

★ ★ ★ ★ ☆

Sanne Noort, Martin Zimmermann, Dirk Reinhardt, Wendy Cuccuini, Martina Pigazzi, Jenny Smith, Rhonda E. Ries, Todd A. Alonzo, Betsy A Hirsch, Daisuke Tomizawa, Franco ...

Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24 ...

Prospective Validation of a New Method of Monitoring ...

★ ★ ☆ ☆ ☆

3/15/2015 · Purpose: This study evaluated the prognostic impact of a novel, simple, and standardized assay for monitoring minimal residual disease (MRD) in pediatric acute myelogenous leukemia (AML). Experimental Design: The expression of seven leukemia-associated genes (WT1, PRAME, CCL23, GAGED2, MSLN, SPAG6, and ST18) was measured by TaqMan Low Density Arrays in 112 patients …

Prospective Validation of a New Method of Monitoring ...

Treatment of Acute Myeloid Leukemia in Adolescent and ...

★ ★ ★ ★ ★

Acute myeloid leukemia (AML) in adolescent and young adult patients (AYAs) may need a different type of therapy than those currently used in children and older patients. As soon as AML is diagnosed, AYA patient should be offered to participate in well-designed clinical trials. ... Recently, the International BFM-Study Group has shown 38% ...

Treatment of Acute Myeloid Leukemia in Adolescent and ...

Residual disease monitoring in childhood acute myeloid ...

★ ★ ★ ☆ ☆

Purpose: Monitoring of residual disease (RD) by flow cytometry in childhood acute myeloid leukemia (AML) may predict outcome.However, the optimal time points for investigation, the best antibody combinations, and most importantly, the clinical impact of RD analysis remain unclear.

Residual disease monitoring in childhood acute myeloid ...

Childhood Acute Lymphoblastic Leukemia Treatment (PDQ ...

★ ★ ☆ ☆ ☆

Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version. ... Children with Down syndrome have an increased risk of developing both ALL and AML, ... a report from the International BFM Study Group. Blood 115 (5): 1006-17, 2010.

Childhood Acute Lymphoblastic Leukemia Treatment (PDQ ...

The Frequency of HLA Class I and II Alleles in Turkish ...

★ ★ ★ ☆ ☆

83 study group trials for AML patients , and ALL-BFM 86 study group trials for ALL patients.26 – 28 The control group consisted of healthy local bone marrow donors and volunteers, age- and sex-matched to the patient groups . The purpose of the study was explained to participants and verbal informed consent was obtained from their parents and ...

The Frequency of HLA Class I and II Alleles in Turkish ...

[Improved treatment results in children with AML: Results ...

★ ★ ★ ☆ ☆

Outcome in high risk patients was superior in study 93 compared to study 87 (remission rate and 5-year pEFS in study AML-BFM 93 vs. study 87: 78 % vs. 68 %, p=0.007, and 44 % vs. 31 %, p logrank=0.01). The placing of HAM as the 2nd or 3rd therapy block was of minor importance.

[Improved treatment results in children with AML: Results ...

Dirk Reinhardt | University of Duisburg-Essen - Academia.edu

★ ★ ★ ☆ ☆

To avoid any bias from additional therapy elements, patients with relapse or initial CNS involvement and transplanted patients were excluded (n=32). Our cohort was representative of the total group of 104 long term survivors of study AML-BFM 87.

Dirk Reinhardt | University of Duisburg-Essen - Academia.edu

The role of matched sibling donor allogeneic stem cell ...

★ ★ ☆ ☆ ☆

high-risk acute myeloid leukemia remains controversial. In the multi-center AML-BFM 98 study we prospectively evaluated the impact of allogeneic stem cell transplantation in children with high-risk acute myeloid leukemia in first complete remission. Design and Methods HLA-typed patients with high-risk acute myeloid leukemia, who achieved first ...

The role of matched sibling donor allogeneic stem cell ...

Prospective Validation of a New Method of ...

★ ★ ★ ★ ☆

ples. This study was approved by institutional review board and was conducted in accordance with the Declaration of Helsinki. AML-BFM 2004 risk group definition Chemotherapy in study AML-BFM 2004 consisted of four coursesforstandard-risk(SR)patientsandfivecoursesforhigh-risk patients (1). SR was defined as FAB (French–American–

Prospective Validation of a New Method of ...

Acute Myeloid Leukemia | Oncohema Key

★ ★ ★ ☆ ☆

In the Children’s Cancer Group (CCG) 2891 study, allo-SCT had a significantly better DFS and OS than did chemotherapy or auto-SCT . However, no difference was observed in trials AML BFM 98, European Organization of Research and Treatment of Cancer (EORTC) Children’s Leukemia Group (CLG) 58,921, and MRC AML 10 . As risk stratification by ...

Acute Myeloid Leukemia | Oncohema Key

Jiri Schwarz - Institute of Hematology and Blood Transfusion

★ ★ ★ ★ ★

Since 1983 four consecutive unified regimens: acute myeloid leukemia-Polish pediatric leukemia/lymphoma study group (AML-PPLLSG) 83, AML-PPLLSG 94, AML-PPLLSG 98 and AML-BFM 2004 Interim, for AML have been conducted by the Polish …

Jiri Schwarz - Institute of Hematology and Blood Transfusion

Development of treatment and clinical results in childhood ...

★ ★ ★ ★ ★

1 3 Development of treatment and clinical results in childhood AML in Austria (1993–2013) 63 ... For the AML BFM-Austria study group. Heidrun Boztug and Nora Mühlegger contributed equally. M. Dworzak ( ) · H. Boztug · N. Mühlegger · E. Glogova · ... Development of treatment and clinical results in childhood AML in Austria (1993–2013) ...

Development of treatment and clinical results in childhood ...

UpToDate

★ ★ ★ ★ ☆

Gröschel S, Schlenk RF, Engelmann J, et al. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J …

UpToDate

Infections in children with down syndrome and acute ...

★ ★ ★ ★ ☆

12/2/2013 · Children with Down syndrome (DS) are at high risk of infectious toxicity when treated with acute lymphoblastic leukemia chemotherapy protocols optimized in children without DS. Our objective was to determine if children with DS and acute myeloid leukemia (AML) have a different risk of infection when treated with chemotherapy protocols developed for children with DS compared to AML treatment ...

Infections in children with down syndrome and acute ...

Childhood Acute Myeloid Leukemia Treatment (PDQ®)—Health ...

★ ★ ★ ☆ ☆

Creutzig U, Ritter J, Schellong G: Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 75 (10): 1932-40, 1990. [PUBMED Abstract]

Childhood Acute Myeloid Leukemia Treatment (PDQ®)—Health ...

Minimal residual disease in acute myeloid leukemia: coming ...

★ ★ ★ ☆ ☆

12/8/2012 · Minimal residual disease in acute myeloid leukemia: coming of age ... the MRD-AML-BFM study group. ... Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98 (6): 1746 – 1751. Abstract / ...

Minimal residual disease in acute myeloid leukemia: coming ...

Second Hematopoietic Stem Cell Transplantation for Post ...

★ ★ ☆ ☆ ☆

Outcome data were collected from the European Society for Blood and Marrow Transplantation registry on 373 children from 120 centers with relapsed leukemia (214 with acute lymphoblastic leukemia [ALL] and 159 with acute myelogenous leukemia [AML]) who underwent second allogeneic hematopoietic stem cell transplantation (HSCT) between 2004 and 2013.

Second Hematopoietic Stem Cell Transplantation for Post ...
Biopace-study-escitalopram.html,Bird-food-study-organization.html,Bitesize-physics-electricity-study.html,Black-ethnic-study-why.html,Black-gold-inc-case-study.html